knowledge -WSS

knowledge

author：leisure time 2025-09-29 20:53:30 - browse：64

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Telehealth options flood the market as retailers push virtual care

knowledge

WSS

Physicians aren't 'burning out.' They're suffering from moral injury

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Readout Newsletter: XBI biotech index, Akero Therapeutics

Cassava reveals details — and problems — with Alzheimer's study

Chris Christie meets with Zelenskyy during Ukraine trip

explore

knowledge

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

'Null' research findings aren't empty of meaning. Let's publish them

Continuity nursing helped my family in our darkest PICU moments

Chimpanzees, like humans and whales, get menopause: Study

Novavax promises a turnaround & Lilly roils the obesity market

Meta's Zuckerberg and Chan on track to put $50 billion into science

New air purifier tech could be key to improving indoor air quality

Testing for cancer recurrence creates a new limbo for patients

Novavax promises a turnaround & Lilly roils the obesity market

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

focus

Study links childhood stress with decline in older age

Readout Newsletter: What happened with Sarepta's Duchenne data

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Chris Christie meets with Zelenskyy during Ukraine trip

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Biden's order seeks to regulate AI risk without stifling innovation

Wikipedia

hotspot

knowledge

hotspot